4//SEC Filing
JACOB LEONARD S 4
Accession 0001209191-19-024300
CIK 0001016169other
Filed
Apr 9, 8:00 PM ET
Accepted
Apr 10, 5:49 PM ET
Size
12.9 KB
Accession
0001209191-19-024300
Insider Transaction Report
Form 4
JACOB LEONARD S
Director
Transactions
- Exercise/Conversion
Common Stock
2019-04-08$0.53/sh+30,000$15,900→ 331,970 total - Exercise/Conversion
Stock Option (right to buy)
2019-04-08−30,000→ 0 totalExercise: $0.53Exp: 2019-05-14→ Common Stock (30,000 underlying) - Exercise/Conversion
Common Stock
2019-04-08$0.53/sh+62,078$32,901→ 301,970 total - Sale
Common Stock
2019-04-08$3.00/sh−92,078$276,243→ 239,892 total - Exercise/Conversion
Stock Option (right to buy)
2019-04-08−62,078→ 0 totalExercise: $0.53Exp: 2019-05-14→ Common Stock (62,078 underlying)
Footnotes (2)
- [F1]The stock option exercises and sale of common stock reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. The stock options were due to expire on May 14, 2019.
- [F2]The options vested and became exercisable in four equal quarterly installments following the grant date of May 14, 2009.
Documents
Issuer
ANTARES PHARMA, INC.
CIK 0001016169
Entity typeother
IncorporatedNY
Related Parties
1- filerCIK 0001049713
Filing Metadata
- Form type
- 4
- Filed
- Apr 9, 8:00 PM ET
- Accepted
- Apr 10, 5:49 PM ET
- Size
- 12.9 KB